Avadel to Unveil New Data on Lumryz for Narcolepsy Treatment

Avadel Pharmaceuticals will present new data supporting the clinical profile for Lumryz for narcolepsy in 12 abstracts at SLEEP 2023.

Related Keywords

United States ,France ,American ,Jennifer Gudeman ,Clete Kushida ,Yves Dauvilliers ,Michaelj Thorpy ,Anne Marie Morse ,Stanford Center ,Stanford University Medical Center ,Albert Einstein College Of Medicine ,Office Of Orphan Product Development ,American Academy Of Sleep ,Wake Disorders Center At Montefiore ,Avadel Pharmaceuticals ,Wake Disorders Centre ,Drug Administration ,Human Sleep Research At Stanford University ,Orphan Drug Exclusivity ,Orphan Product Development ,Risk Evaluation ,Mitigation Strategy ,American Academy ,Sleep Medicine Established ,Unmet Medical Needs ,New Narcolepsy ,Geisinger Medical Center ,Janet Weis Children ,Gui De Chauliac Hospital ,Sleep Wake Disorders Center ,Albert Einstein College ,Stanford Sleep Medicine ,Human Sleep Research ,